DRUG AND ALCOHOL DEPENDENCE
An International Journal on Biomedical and Psychosocial Approaches
Sponsored by the external link College on Problems of Drug Dependence

Editor Conflict of Interest Statements

DRUG AND ALCOHOL DEPENDENCE

Authors, reviewers and readers may want to know about potential conflicts of interest that may arise with journal editors in the processing of submissions. Journal policy precludes editors from serving as the assigned editor on any paper on which they appear as an author. In general, editors will not serve as the assigned editor for submissions arising from within their own institution, although there may be exceptions to this if there is no clear association of the editor and author or their respective departments. Editors are also asked to excuse themselves from assignments where they have a personal conflict which might preclude conducting a fair and impartial review process. In addition to these general principals, listed below is specific financial information for each of the journal editors covering the past three years. Editors will also excuse themselves for submissions where conflicts exist regarding these outside financial interests, if any.

Eric C. Strain is a Professor in the Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine. His academic salary is provided by a K24 grant from the National Institute on Drug Abuse, other NIH grants, as well as funds from Johns Hopkins University. Dr. Strain is a current and past recipient of NIDA research grants. Each year he typically receives honoraria for his services on behalf of the U.S. federal government (e.g., grant reviews) and from academic medical centers (e.g., providing grand rounds). He also receives modest royalties from textbooks he has co-edited. Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Strain for his efforts as Editor-in-Chief of the journal. This honorarium is increased for additional duties in the processing of supplemental issues of the journal. The publisher also provides some funds to cover editorial expenses in the journal office. In the past three years Dr. Strain has received outside income by providing consulting and speaking services to pharmaceutical companies, other related health service companies, and expert work on forensic cases. In the past three years he has provided consulting and speaking services to pharmaceutical companies (Abbott, Grunenthal, Reckitt-Benckiser, and Shire Pharmaceuticals), he has received research contracts from companies for drug-related research (Fast-Track Drugs and Biologics, Reckitt-Benckiser), consulted for health service companies (The Oak Group, Friends Research Institute), and served as an expert review of forensic cases (with reimbursement for these services by local and national law firms associated with these cases). Dr. Strain's family has small equity holdings in companies with prominent sales of caffeine-containing beverages, and in one pharmaceutical company (Gilead Sciences). Dr. Strain currently has no other investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to his service as Editor-in-Chief aside from possible inclusion in mutual funds over which he has no control as an individual investor. (Updated June of 2010).

Jan Copeland is a Professor in the Faculty of Medicine at the University of New South Wales. She is Director of the National Cannabis Prevention and Information Centre (NCPIC) and an Assistant Director of the National Drug and Alcohol Research Centre at that University. Her academic salary is provided by the Australian Government's Department of Health and Ageing as the NCPIC funder. She is a past recipient of a NIDA research grant, grants from the Australian National Health and Medical Research Council, the NSW Health Department, ZonMW and the Australian Rotary Health Fund. Each year she typically receives honoraria to attend conferences or provide training. Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Professor Copeland for her efforts as an Assistant Editor of the journal. Professor Copeland has never received any funds from pharmaceutical companies but is involved in a clinical trial of a medication that is being provided free of charge by the manufacturer. Professor Copeland has no investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to her service as Assistant Editor aside from possible inclusion in superannuation funds over which she has no control as an individual investor. (Updated February 2011).

Deborah S. Hasin is Clinical Professor of Epidemiology in the Department of Psychiatry at the College of Physicians and Surgeons, Columbia University, with a secondary appointment in the Department of Epidemiology in the Mailman School of Public Health, Columbia University. Her academic salary is provided by a K05 grant from NIAAA, and from New York State Psychiatric Institute. Dr. Hasin is a current and past recipient of NIDA and NIAAA research grants, as well as contracts from NIAAA and Westat. Each year she typically receives honoraria for her services on behalf of the U.S. federal government e.g., serving on the National Advisory Council to NIAAA) and from academic medical centers (e.g., providing grand rounds). Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Hasin for her efforts as an Associate Editor of the journal. Dr. Hasin currently has no investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to her service as an Associate Editor aside from possible inclusion in mutual funds over which she has no control as an individual investor. (Updated July of 2010).

Kyle M. Kampman is an Associate Professor in the Department of Psychiatry at The University of Pennsylvania School of Medicine. His academic salary is supported by grants from the NIH as well as funds from the University of Pennsylvania. In the past three years, he has received honoraria for his services on behalf of the U.S. federal government (e.g., grant reviews) and from academic medical centers (e.g., providing grand rounds). He also has received honoraria for continuing medical education events sponsored by Reckitt Benkiser, Alkermes, and Cephalon. Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Kampman for his efforts as an Associate Editor of the journal. Dr. Kampman currently has no investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to his service as an Associate Editor, aside from possible inclusion in mutual funds over which he has no control as an individual investor. (Updated June of 2010).

Lin Lu is a Professor and the Director of National Institute on Drug Dependence, Peking University, China. He has a full-time appointment at Peking University Health Science Center and his academic salary is provided directly by Peking University. Dr. Lu is a current and past recipient of research grants from Natural Science Foundation of China and Department of Nature and Science, China. Each year he typically receives honoraria for his services on behalf of the China government (e.g., committee meetings). He also receives small royalties from textbooks he has co-edited. Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Lu for his efforts as an Associate Editor of the journal. In the past three years Dr. Lu has received a modest outside income by providing consulting and speaking services to pharmaceutical companies and other related health service companies. In the past five years he has provided consulting and speaking services to different pharmaceutical companies (Lilly, Pfizer and Reckitt-Benckiser). Dr. Lu currently has no other investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to his service as Associate Editor aside from possible inclusion in mutual funds over which he has no control as an individual investor. (Updated July of 2010).

Marcus Munafò is Professor of Biological Psychology at the University of Bristol in the United Kingdom. His academic salary is provided by the University of Bristol, through HEFCE funding. He has received research funding from the National Health Service and various research councils and charities, which have included the Alcohol Education and Research Council, the European Research Advisory Board and Pfizer. In addition, he has received nicotine replacement products from GlaxoSmithKline and Pfizer for distribution to study participants. He has received consulting fees from the American Institutes for Research, the European Commission, G-Nostics Ltd, the National Audit Office, and Servier. He has received honoraria for invited lectures from GlaxoSmithKline, Novartis and Sepracor, and from various academic institutions, as well as honoraria for editorial activities for Addiction, Nicotine and Tobacco Research and Drug and Alcohol Dependence. He receives royalties from academic books he has published. He currently is listed as a co-inventor on a patent for the use of carbon-dioxide enriched air in the treatment of addiction. He has no equity holdings in pharmaceutical, tobacco or alcohol companies aside from possible inclusion in mutual funds over which he has no control as an individual investor. (Updated August of 2011).

Linda J. Porrino is a Professor and Chair of the Department of Physiology and Pharmacology at Wake Forest University School of Medicine. Her academic salary is provided by grants from the National Institute of Health, as well as funds from Wake Forest University School of Medicine. Dr. Porrino is a current and past recipient of NIDA and NIAAA research grants, as well as grants from the Defense Advanced Research Programs Agency. Each year she typically receives honoraria for her services on behalf of the U.S. federal government (e.g., grant reviews) and from academic medical centers (e.g., providing grand rounds). Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Porrino for her efforts as an Associate Editor of the journal. Dr. Porrino currently has no investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to her service as an Associate Editor aside from possible inclusion in mutual funds over which she has no control as an individual investor. (Updated June of 2010).

Craig R. Rush is a Professor in the Departments of Behavioral Science, Psychiatry and Psychology at the University of Kentucky. His academic salary is provided by funds from the University of Kentucky. Dr. Rush is a current and past recipient of NIDA research grants. Each year he typically receives honoraria for his services on behalf of the U.S. federal government (e.g., grant reviews) and from academic medical centers (e.g., speaking engagements). Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Rush for his efforts as and Associate Editor of the journal. In the past three years Dr. Rush has served as an expert reviewer of forensic cases (with reimbursement for these services by local law firms associated with these cases). Dr. Rush's family has small equity holdings in one biotech company (Vivus). Dr. Rush currently has no other investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to his service as an Associate Editor aside from possible inclusion in mutual funds over which he has no control as an individual investor. (Updated June of 2010).

Steffanie A. Strathdee is Professor, Harold Simon Chair and Chief of the Division of International Health and Cross Cultural Medicine in the Department of Family and Preventive Medicine at the University of California, San Diego School of Medicine. She is also an Adjunct Professor in the Department of Epidemiology at Johns Hopkins University. Her salary support is provided in part from the University of California and research grants from the National Institute of Health, particularly the National Institute on Drug Abuse. Conflicts of interests exist by virtue of her research collaborations and co-funding with certain faculty members at the Johns Hopkins School of Public Health and the University of British Columbia. Dr. Strathdee periodically receives honoraria for lectures on research topics related to HIV and drug abuse, and grant proposal reviews for the National Institutes of Health. Currently or in the past, Dr. Strathdee has had no investments in pharmaceutical, tobacco, alcohol beverage or other firms with entrepreneurial activities. She receives an honorarium from Elsevier for her service as Associate Editor of Drug and Alcohol Dependence. (Updated July, 2010).

Wim van den Brink is a Professor of Psychiatry and Addiction at the Academic Medical Center of the University of Amsterdam, The Netherlands. He has a full-time tenure appointment at the Academic Medical Center and his academic salary is provided directly by the University of Amsterdam. Dr. van den Brink is a current and past recipient of ZonMW and NIDA research grants. Each year he typically receives honoraria for his services on behalf of the Dutch government (e.g., committee meetings). He also receives modest royalties from textbooks he has co-edited. Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. van den Brink for his efforts as an Associate Editor of the journal. In the past three years Dr. van den Brink has received a modest outside income by providing consulting and speaking services to pharmaceutical companies and other related health service companies. In the past three years he has provided consulting and speaking services to different pharmaceutical companies (Lilly, Pfizer, Schering-Plough/MSD, Merck-Serono, Solvay-Abbott), and he has received research contracts from companies for drug-related research (Merck-Serono, Tibotec, Lundbeck). Dr. Van den Brink has equity holdings in pharmaceutical companies aside from possible inclusion in mutual funds over which he has no control as an individual investor. (Updated July 2010).
Drug and Alcohol Dependence